Systemic maternal inflammation promotes ASD via IL-6 and IFN-γ. Issue 11 (16th November 2022)

• Record Type: Journal Article
• Authors: Majerczyk, Daniel; Ayad, Elizabeth G.; Brewton, Kari L.; Saing, Pichrasmei; Hart, Peter C.
• Is Part Of: Bioscience reports. Volume 42:Issue 11(2022)
• Publication Date: 2022-11-16
• Subjects: ASD -- autism-spectrum disorders -- interferon-gamma -- interleukin 6 -- maternal immune activation -- MIA; Molecular biology -- Periodicals; Cytology -- Periodicals; 572.8
• DOI: 10.1042/BSR20220713
• Languages: English
• ISSNs: 0144-8463

Abstract

Abstract: Autism spectrum disorder (ASD) is a neurological disorder that manifests during early development, impacting individuals through their ways of communicating, social behaviors, and their ability to perform day-to-day activities. There have been different proposed mechanisms on how ASD precipitates within a patient, one of which being the impact cytokines have on fetal development once a mother's immune system has been activated (referred to as maternal immune activation, MIA). The occurrence of ASD has long been associated with elevated levels of several cytokines, including interleukin-6 (IL-6) and interferon gamma (IFN-γ). These proinflammatory cytokines can achieve high systemic levels in response to immune activating pathogens from various extrinsic sources. Transfer of cytokines such as IL-6 across the placental barrier allows accumulation in the fetus, potentially inducing neuroinflammation and consequently altering neurodevelopmental processes. Individuals who have been later diagnosed with ASD have been observed to have elevated levels of IL-6 and other proinflammatory cytokines during gestation. Moreover, the outcome of MIA has been associated with neurological effects such as impaired social interaction and an increase in repetitive behavior in animal models, supporting a mechanistic link between gestational inflammation and development of ASD-like characteristics. The present review attempts to provide a concise overview of the available preclinical and clinical data that suggest cross-talk between IL-6 and IFN-γ through both extrinsic and intrinsic factors as a central mechanism of MIA that may promote the development of ASD.